HCPCS Code J7502: Cyclosporine, oral, 100 mg billing guide

Key takeaways

HCPCS Code J7502 describes cyclosporine, oral, 100 mg, a Level II J-code for immunosuppressive drug billing.

Medicare Part B covers J7502 post-transplant, but oral cyclosporine has a specific Part B exception that must be documented correctly.

One unit is 100 mg, so a 200 mg dispensing bills two units and a 25 mg dose moves to J7515.

Reimbursement follows ASP methodology and CMS updates it quarterly. Check the current quarter’s file before you quote a dollar figure.

Pabau’s claims management software supports HCPCS drug code workflows, NDC crosswalk lookups, and claim scrubbing to reduce J7502 denials.

HCPCS Code J7502 describes cyclosporine, oral, 100 mg, and sits in the J7500 series that HCPCS Level II reserves for immunosuppressive drugs. One unit equals one 100 mg dose. Medicare Part B covers it after a transplant under a narrow exception for oral drugs.

This guide covers the code’s official description, Part B coverage rules, ASP reimbursement, and the NDC crosswalk. It also walks through the buy-and-bill process and the related J-codes billing teams need alongside J7502.

HCPCS Code J7502: Definition and code details

HCPCS Code J7502 is maintained by the Centers for Medicare and Medicaid Services (CMS) as part of the HCPCS Level II code set. It reports a single 100 mg oral dose of cyclosporine or cyclosporine modified. The table below captures the core code metadata billing teams need before submitting a claim.

One practical point: HCPCS Level II codes like J7502 are distinct from CPT codes. CMS maintains the J-series for drugs and biologicals billed outside the physician fee schedule.

That makes it the correct code set for immunosuppressive drug claims. Coders can confirm current code status through the AAPC HCPCS lookup before they build the claim line.

Clinical use and medical indications for cyclosporine

Cyclosporine is a calcineurin inhibitor that suppresses T-cell-mediated immune responses. Its primary clinical role is preventing acute rejection following solid organ transplantation. Medical necessity documentation for HCPCS Code J7502 claims must reflect one of these established indications.

• Kidney transplant rejection prophylaxis — the most common post-transplant indication billed under J7502
• Liver transplant maintenance — cyclosporine used as part of an immunosuppressive regimen following liver transplant
• Heart transplant maintenance — cardiac transplant recipients often require long-term cyclosporine therapy
• Rheumatoid arthritis — Part B coverage here is far more restricted than for post-transplant use, so document carefully and check your MAC’s guidance
• Psoriasis — the same restriction applies, and MAC-level Local Coverage Determinations govern how dermatology practices bill it

Transplant pharmacies supporting prescription management workflows need to distinguish between cyclosporine (non-modified, sold as Sandimmune) and cyclosporine modified (Neoral, Gengraf).

The two formulations have different bioavailability profiles and are not bioequivalent, but both map to HCPCS Code J7502 for billing purposes. The distinction matters clinically and for NDC crosswalk accuracy, not for the J-code itself.

Medicare Part B coverage for cyclosporine: The oral drug exception

Oral drugs usually fall under Medicare Part D rather than Part B coverage. Cyclosporine post-transplant is one of a narrow set of exceptions carved out under the Part B immunosuppressive drug benefit. Confirming insurance eligibility verification before dispensing is the fastest way to avoid a coverage dispute between Part B and Part D.

The Part B exception applies when the patient received a Medicare-covered organ transplant and the drug is used for immunosuppressive therapy. CMS authority for this benefit sits in the Medicare Benefit Policy Manual, Chapter 15.

Check the relevant National Coverage Determination before you bill. Then check whether your MAC has issued a Local Coverage Determination that narrows or expands coverage for a specific indication.

Important caveat: Medicare coverage criteria change periodically. Always verify current NCD and MAC LCD status before billing. The table above reflects the general framework as of publication. Dollar thresholds, formulary position, and prior-authorization rules are set at the MAC level.

J7502 fee schedule and ASP reimbursement rates

Medicare reimburses J7502 under the Average Sales Price (ASP) methodology. CMS calculates ASP from manufacturer-reported sales data and publishes updated payment limits quarterly, typically effective January, April, July, and October.

Billing staff should pull the current quarter’s ASP pricing file from CMS rather than relying on a prior period’s rates.

The standard payment formula for Part B drugs is ASP plus 6%, and the 2% sequestration reduction comes off the effective payment. No geographic or shortage-area bonus applies to the drug payment itself. The Health Professional Shortage Area bonus covers physician professional services, not Part B drugs.

Verify current rates directly in the CMS Physician Fee Schedule lookup. A billing cycle spent chasing an outdated figure usually costs more in staff time than the quarterly rate check itself.

How to bill J7502: The buy-and-bill process

Under the buy-and-bill model, the provider purchases cyclosporine, dispenses it to the patient, and then submits the claim for reimbursement. Submitting a clean claim the first time is the fastest way to shorten the reimbursement cycle.

The steps below reflect the standard buy-and-bill workflow for immunosuppressive drug billing under Medicare Part B rules. MAC-specific variations apply, so confirm current guidance from your MAC before submitting.

1. Obtain a valid physician order — the prescribing physician or authorized practitioner documents the indication, dose, and frequency. The order must reference the transplant history where applicable.
2. Purchase the drug — acquire cyclosporine (Sandimmune, Neoral, or Gengraf) from a licensed supplier and record the NDC, lot number, and acquisition cost. Those three details feed the superbill and the claim.
3. Verify Part B eligibility — confirm the patient’s Medicare Part B coverage and check whether the transplant itself was Medicare-covered. A transplant funded by a commercial payer before Medicare enrollment changes the coverage picture.
4. Dispense and document administration — record the date, the dose in 100 mg units, and the dispensing provider in the patient record. J7502 bills per 100 mg unit, so a 200 mg dispensing bills two units.
5. Complete the superbill or encounter form — J7502 needs the correct unit count, an NDC with qualifier N4, a supporting diagnosis code, and the physician NPI. A Z94.x transplant status code usually sits alongside the primary condition. Review superbill documentation if your team is new to J-code claims.
6. Submit the claim — file on the CMS-1500 form or the equivalent 837P electronic transaction, with the NDC in Box 24D. Retain acquisition cost records, because some MACs request cost documentation during an audit.
7. Track remittance and follow up on denials — apply the denial management strategies that suit J-code claims. CO-96 and CO-4 are the two rejections J7502 claim errors trigger most often.

Critical compliance note: CMS generally classifies self-administered drugs as Part D, and oral cyclosporine is self-administered at home under most treatment protocols. The post-transplant immunosuppressive drug benefit is a specific Part B carve-out. Billing J7502 under Part B for a non-exempt indication is improper billing.

Consult CMS Pub. 100-02, Chapter 15 for the authoritative framework. Also review your obligations under HIPAA-compliant documentation standards when you retain acquisition and dispensing records.

NDC to HCPCS crosswalk

Every J7502 claim to Medicare needs a National Drug Code (NDC) in the right format. That means an 11-digit NDC with qualifier N4, in Box 24D on the CMS-1500 or the equivalent 837P loop.

CMS publishes a quarterly NDC-to-HCPCS crosswalk file that maps product-level NDCs to the matching J-code. Checking it before submission catches the product mismatches that trigger automatic denials.

The primary branded and generic products that map to J7502 are listed below. NDC numbers change when manufacturers update lot configurations or discontinue products. Treat this table as a reference framework and confirm against the current CMS crosswalk file.

When billing units, each J7502 unit equals 100 mg. A patient dispensed 200 mg on a given date receives two units of J7502 on that claim line. The NDC reported should match the specific product dispensed rather than a generic placeholder.

Coverage criteria and documentation requirements

Incomplete documentation is the most common reason J7502 claims face post-payment audit recoupment. Proper medical billing fundamentals require that every claim be supported by a contemporaneous clinical record. The checklist below reflects the documentation standard most MACs apply to J7502 claims.

• Transplant history — document the organ transplanted, the transplant date, and the facility where it happened. Include this in the patient record and in the claim’s supporting documentation.
• Physician order — a valid, dated order specifying cyclosporine, the dose in mg, the frequency, and the indication. Orders older than 12 months are frequently flagged during MAC audits.
• Medical necessity statement — a note from the treating physician explaining why cyclosporine is medically necessary for this patient, referencing the transplant or the diagnosed condition.
• Drug administration records — dispensing logs showing the date, product NDC, lot number, dose dispensed, and the dispensing provider’s signature. For buy-and-bill, this is the primary evidence that the drug left the practice.
• Diagnosis codes — report the appropriate Z94.x transplant status code alongside any active condition code. Do not bill J7502 without a diagnosis code that justifies immunosuppressive therapy.
• ABN, if applicable — where Part B coverage is in question, issue a signed Advance Beneficiary Notice before dispensing. Keep a copy in the patient file.

Four codes account for most J7502 rejections, and each one names a different failure. Working from the denial code rather than the dollar amount is what makes an appeal land.

• CO-96: non-covered charge. Usually means the transplant was not Medicare-covered, or the indication does not qualify for the Part B exception.
• CO-4: modifier required. Check whether your MAC expects a modifier on oral drug claims billed under buy-and-bill.
• CO-197: precertification, authorization or notification absent. Some carriers require prior authorization for cyclosporine beyond a set duration.
• CO-16: claim lacks information. Most often triggered by a missing or badly formatted NDC in Box 24D.

Related HCPCS codes for immunosuppressive drug billing

Transplant programs typically bill multiple immunosuppressive agents for the same patient. Knowing the related codes in the J7500 series prevents unbundling errors and helps billing teams build correct multi-drug claim lines.

J7515 is the code to use when a patient’s dose has been titrated down to 25 mg. Never bill J7502 for a 25 mg dispensing, even when cyclosporine modified is the same product.

Billing the wrong unit size is a Medically Unlikely Edit flag and a common audit trigger. The mapping below shows how a dispensed dose becomes a code and a unit count.

How Pabau keeps J-code claim lines accurate

Practices running transplant programs, and the primary care practices that maintain those patients long term, juggle a rotating roster of J-codes. Manual NDC entry and quarterly rate refreshes are the two steps where billing errors concentrate.

Practice management software like Pabau closes both steps. Pabau’s claims management software automates the NDC-to-J-code crosswalk lookup, flags mismatched unit counts, and scrubs each claim before it reaches the payer. So CO-16 and CO-4 errors surface at submission rather than six weeks later on a remittance.

Electronic claims leave Pabau through its Claim.MD integration, so the 837P and the returning ERA land in the same patient record. Built-in drug code management holds HCPCS Level II claim lines alongside procedure codes, so a transplant patient’s multi-code claim gets built in one place.

Pabau also fits the wider medical billing software stack, with denial tracking and payment posting in the same dashboard. That keeps the J7502 revenue cycle visible to the billing team without a second login.

Streamline immunosuppressive drug billing with Pabau

Pabau’s claims management tools help transplant and specialty practices submit accurate J-code claims, track NDC crosswalks, and reduce cyclosporine billing denials before they happen.

Book a demo

Conclusion

A J7502 claim is decided before it is submitted. The formulation you documented, the NDC you entered, and the unit count you calculated either agree with the dispensing record or they do not.

So the habit worth building is quarterly rather than per-claim. Pull the current ASP file before you quote a figure, and read the denial code before you appeal.

The trade-off is that the buy-and-bill model puts the acquisition cost and the reimbursement risk on your practice. Software that catches the unit count and the NDC at submission is what keeps that risk small. Book a demo to see how Pabau handles J-code billing for a specialty practice.

Continue your research

Billing another Part B drug under buy-and-bill? J1556 covers the immune globulin equivalent, including unit math and NDC reporting.

Need the same breakdown for an injectable J-code? J0132 sets out the descriptor, coverage rules, and documentation a payer expects.

Want eligibility checks done before the patient arrives? Patient onboarding software shows how intake, consent, and insurance capture fit into one workflow.

Frequently asked questions